Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04517838 · ClinicalTrials.gov registry record
Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer
A clinical trial of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 230
- Enrollment target
- 1
- Study location
NCT04517838 is a study of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8 that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 230 participants, below the 302-participant average among 84 other Anatomic Stage III Breast Cancer AJCC v8 trials with a reported enrollment target (24% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04517838, a study of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 230 participants
- Enrollment target
- 1
- Study location
Study Summary
This study gathers information from the blood cells and tumor tissue during treatment with anti-HER2 therapies, such as trastuzumab, pertuzumab, lapatinib, or neratinib, in patients with HER2 positive stage I-IV breast cancer who are scheduled to start anti-HER2 therapy. The information gained from this study may help researchers better understand the relation between cell response and anti-HER2 therapies.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
Study Locations (1)
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2020-07-31 |
| Est. Completion | 2028-07-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04517838
The ClinicalTrials.gov registry entry for NCT04517838 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 302-participant average among 84 other Anatomic Stage III Breast Cancer AJCC v8 trials with a reported enrollment target (24% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Anatomic Stage III Breast Cancer AJCC v8 appearing as the primary indexed condition, and to 1 intervention - of which Biospecimen Collection is the first listed.
NCT04517838 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04517838 about?
NCT04517838 is a clinical study titled "Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer". This study gathers information from the blood cells and tumor tissue during treatment with anti-HER2 therapies, such as trastuzumab, pertuzumab, lapatinib, or neratinib, in patients with HER2 positive stage I-IV breast cancer who are scheduled to start anti-HER2 therapy. The information gained from ...
What is the current status of trial NCT04517838?
This trial is currently recruiting. The enrollment target is 230 participants. The study started on 2020-07-31. Estimated completion is 2028-07-27.
What conditions does trial NCT04517838 study?
This clinical trial studies the following conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma.
What interventions are being tested in trial NCT04517838?
The interventions under investigation include: Biospecimen Collection (PROCEDURE).
Who is sponsoring clinical trial NCT04517838?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04517838 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anatomic Stage III Breast Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
A Quality of Life Intervention for Young African American Breast Cancer Survivors in Treatment
RECRUITING · NA
-
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RECRUITING · Phase 2
-
Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
RECRUITING · NA
-
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 2
-
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 4
Explore more on PlainTrial
Anatomic Stage III Breast Cancer AJCC v8
All registered trials for this condition
Anatomic Stage II Breast Cancer AJCC v8
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.